<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04857307</url>
  </required_header>
  <id_info>
    <org_study_id>UP0100</org_study_id>
    <nct_id>NCT04857307</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Pharmacokinetics (PK) and Safety of Staccato Alprazolam in Adolescent Study Participants With Epilepsy</brief_title>
  <official_title>A Multicenter, Open-Label Study to Evaluate the Pharmacokinetics, Tolerability, and Safety of a Single Dose of Staccato Alprazolam in Adolescent Study Participants With Epilepsy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UCB Biopharma SRL</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UCB Pharma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to assess the pharmacokinetics (PK), tolerability, and safety of&#xD;
      Staccato alprazolam in adolescent study participants with epilepsy following single-dose&#xD;
      administration.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 28, 2021</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum plasma concentration (Cmax) following single inhaled dose of Staccato alprazolam</measure>
    <time_frame>Plasma samples will be taken on Day 1 of the Treatment Period, predose and then following administration of Investigational Medicinal Product (IMP) at 2 minutes, 10 minutes, 30 minutes, 1 hour, 2 hours, 6 hours, 24 hours, and 36 hours postdose.</time_frame>
    <description>Cmax = Maximum plasma concentration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve from zero to the last quantifiable concentration (AUC(0-t)) following single inhaled dose of Staccato alprazolam</measure>
    <time_frame>Plasma samples will be taken on Day 1 of the Treatment Period, predose and then following administration of Investigational Medicinal Product (IMP) at 2 minutes, 10 minutes, 30 minutes, 1 hour, 2 hours, 6 hours, 24 hours, and 36 hours postdose.</time_frame>
    <description>AUC(0-t) = Area under the plasma concentration-time curve from zero to the last quantifiable concentration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve from time 0 to infinity (AUC) following single inhaled dose of Staccato alprazolam</measure>
    <time_frame>Plasma samples will be taken on Day 1 of the Treatment Period, predose and then following administration of Investigational Medicinal Product (IMP) at 2 minutes, 10 minutes, 30 minutes, 1 hour, 2 hours, 6 hours, 24 hours, and 36 hours postdose.</time_frame>
    <description>AUC = Area under the plasma concentration-time curve from time 0 to infinity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent total body clearance (CL/F) following single inhaled dose of Staccato alprazolam</measure>
    <time_frame>Plasma samples will be taken on Day 1 of the Treatment Period, predose and then following administration of Investigational Medicinal Product (IMP) at 2 minutes, 10 minutes, 30 minutes, 1 hour, 2 hours, 6 hours, 24 hours, and 36 hours postdose.</time_frame>
    <description>CL/F = Apparent total body clearance.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants with treatment-emergent adverse event (TEAEs)</measure>
    <time_frame>From baseline (Day 1) till end of Safety Follow-up (up to Day 9)</time_frame>
    <description>An Adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant temporally associated with the use of IMP, whether or not considered related to the IMP.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants with serious treatment-emergent adverse event (serious TEAEs)</measure>
    <time_frame>From baseline (Day 1) till end of Safety Follow-up (up to Day 9)</time_frame>
    <description>A serious adverse event (SAE) is defined as any untoward medical occurrence that, at any dose:&#xD;
a. Results in death c. Requires inpatient hospitalization or prolongation of existing hospitalization d. Results in persistent disability/incapacity e. Is a congenital anomaly/birth defect f. Important medical events.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">14</enrollment>
  <condition>Epilepsy</condition>
  <arm_group>
    <arm_group_label>Staccato alprazolam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The study participants will receive a single dose of Staccato alprazolam.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alprazolam</intervention_name>
    <description>Pharmaceutical form: Inhalation powder.&#xD;
Study participants will receive Staccato alprazolam at prespecified time-points.</description>
    <arm_group_label>Staccato alprazolam</arm_group_label>
    <other_name>UCB7538</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participant must be 12 to 17 years of age inclusive, at the time of signing the&#xD;
             Informed Consent form (ICF) and the Assent form&#xD;
&#xD;
          -  Participant has an established diagnosis of focal, generalized, or focal and&#xD;
             generalized epilepsy&#xD;
&#xD;
          -  Participant is in good general health as determined by medical evaluation including&#xD;
             medical history and physical examination&#xD;
&#xD;
          -  Participants with a body weight â‰¥29 kg and body mass index (BMI) within the range 14&#xD;
             to 32 kg/m^2 (inclusive)&#xD;
&#xD;
          -  A male participant must agree to use contraception&#xD;
&#xD;
          -  A female participant is eligible to participate if she is not pregnant&#xD;
&#xD;
          -  Participant is capable of and provides assent, and the study participant's&#xD;
             parent/legal representative provides signed informed consent for minor study&#xD;
             participants, which includes compliance with the requirements and restrictions listed&#xD;
             in the ICF, Assent form, and in this protocol&#xD;
&#xD;
          -  Participant has a lifetime history of never smoking &gt;5 cigarettes/day, and a current&#xD;
             history (for at least 6 months prior to Screening Visit) of not smoking at all&#xD;
             (including e-cigarette and vaping products)&#xD;
&#xD;
          -  Participant has forced expiratory volume in 1 second (FEV1) and forced vital capacity&#xD;
             (FVC) &gt;80% predicted at Screening. In case of an out-of-range result, 1 repeat test&#xD;
             will be allowed. If the readings are out-of-range again, the study participant will be&#xD;
             excluded&#xD;
&#xD;
          -  Participant is willing and able to be confined to a clinical research facility for up&#xD;
             to 36 hours (including 1 overnight stay) and comply with the study schedule and study&#xD;
             requirements&#xD;
&#xD;
          -  Participant is currently taking at least 1 background antiepileptic drug (AED)&#xD;
&#xD;
          -  Participant is able to actuate the training device during Screening, according to&#xD;
             Instructions for Use&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participant has history or presence of cardiovascular, respiratory, hepatic, renal,&#xD;
             gastrointestinal, endocrinological, neurological, hematological, cerebrovascular, or&#xD;
             other major disorders capable of significantly altering the absorption, metabolism, or&#xD;
             elimination of Investigational Medicinal Product (IMP); constituting a risk when&#xD;
             taking the study intervention; or interfering with the interpretation of data in the&#xD;
             opinion of the Investigator&#xD;
&#xD;
          -  Participant has a known hypersensitivity to any components of the IMP or comparative&#xD;
             drugs (and/or an investigational device) as stated in the protocol&#xD;
&#xD;
          -  Participant has severe chronic cardio-respiratory disease&#xD;
&#xD;
          -  Participant has history of acute narrow angle glaucoma, hydrocephalus, or Myasthenia&#xD;
             Gravis&#xD;
&#xD;
          -  Participant has history or has current airway disease such asthma, cystic fibrosis, or&#xD;
             chronic obstructive pulmonary disease&#xD;
&#xD;
          -  Participant has any acute respiratory signs/symptoms (ie, wheezing) and active acute&#xD;
             respiratory infection (or within 1 week of dosing) with exception of symptoms of mild&#xD;
             rhinitis&#xD;
&#xD;
          -  Participant has a known hypersensitivity to albuterol or similar short-acting&#xD;
             beta2-agonist (SABA) that may be used as rescue medication administered in response to&#xD;
             potential bronchospasm&#xD;
&#xD;
          -  Participant is taking strong liver inducing agents (eg, phenytoin, phenobarbital,&#xD;
             carbamazepine, and primidone) or strong Cytochrome P450 3A4 (CYP3A4) inhibitors&#xD;
&#xD;
          -  Participant has a SpO2 measured by pulse oximetry &lt;95% for &gt;30 seconds during the&#xD;
             Screening Visit&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>UCB Cares</last_name>
    <role>Study Director</role>
    <affiliation>001 844 599 2273 (UCB)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>UCB Cares</last_name>
    <phone>001 844 599 2273</phone>
    <email>UCBCares@ucb.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Up0100 102</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Up0100 103</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Up0100 101</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Up0100 104</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Up0100 108</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Up0100 105</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Up0100 107</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>April 22, 2021</study_first_submitted>
  <study_first_submitted_qc>April 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 23, 2021</study_first_posted>
  <last_update_submitted>October 15, 2021</last_update_submitted>
  <last_update_submitted_qc>October 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Epilepsy</keyword>
  <keyword>Staccato alprazolam</keyword>
  <keyword>Phase 1</keyword>
  <keyword>Adolescents</keyword>
  <keyword>STAP-001</keyword>
  <keyword>Alprazolam</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alprazolam</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Due to the small sample size in this trial, IPD cannot be adequately anonymized i.e., there is a reasonable likelihood that individual participants could be re-identified. For this reason, data from this trial cannot be shared.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

